Hyundai Pharmaceutical Co., Ltd.
KKRX:0043106,790.00
KRW
-200.00
(-2.86%)
ISIN
KR7004310009
Return %
Stock
S&P 500
1Y
79.16
14.39
3Y
84.51
81.42
5Y
13.17
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Sang-Joon Lee
- Full Time Employees
- 399
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Hyundai Pharm Building Cheonan SC South Korea 06121
- IPO Date
- Jun 28, 1978
- Website
- hyundaipharm.co.kr
- Similar Companies
- Business
- Hyundai Pharmaceutical Co., Ltd. is a South Korea-based company primarily engaged in the development, manufacture, and distribution of pharmaceutical products, health food drinks, and medical devices. Founded in 1989 and headquartered in Seoul, the company offers a broad portfolio of core pharmaceutical products including ethical and over-the-counter (OTC) drugs across multiple therapeutic areas such as cardiovascular diseases, endocrine disorders (notably diabetes), central nervous system conditions (including depression, schizophrenia, Alzheimer’s, and Parkinson’s), pain management, women’s health, respiratory ailments, oncology, and dermatology. Key pharmaceutical product categories include antianginals, antibiotics, antiemetics, antihistamines, antihyperlipidemics, antihypertensives, antiplatelet agents, antitussives, and cell stimulants. In addition to pharmaceuticals, Hyundai Pharm markets health food beverages and medical devices domestically and explores diverse partnership opportunities such as licensing, co-marketing, co-promotion, and joint ventures with global pharmaceutical companies. Recent major developments include Hyundai Pharmaceutical’s exclusive licensing and commercialization agreement signed in 2023 with Cosmo Pharmaceuticals for the dermatology product Winlevi® (clascoterone) cream 1%, approved by South Korean regulatory authorities in 2025 for treating acne vulgaris. This strategic alliance leverages Cosmo’s global dermatology innovation and Hyundai Pharm’s local expertise to address unmet acne treatment needs in Korea. Moreover, Hyundai Pharm has patented novel USP1 inhibitors targeting cancer treatments, reflecting its expanding focus on oncology innovation. The company also maintains various exclusive distribution and licensing agreements for products like Kytril (antiemetic), Twyneo and Epsolay (acne and rosacea treatments), and Bijuva (menopausal hormone therapy), emphasizing its continued expansion into specialty pharmaceuticals and women's health markets. Hyundai Pharm’s operations focus predominantly on South Korea, with active collaborations and licensing agreements facilitating its product portfolio and pipeline diversification. Overall, Hyundai Pharmaceutical Co., Ltd. stands as an integrated pharmaceutical company with a comprehensive product lineup across major therapeutic areas, supplemented by strategic international partnerships and recent advancements in dermatology and oncology products, positioning it for sustained growth within the South Korean pharmaceutical industry.